BOTHELL, Wash., June 11, 2026
Immunome, Inc. announced the first patient has been dosed in a Phase 1 first-in-human clinical trial evaluating IM-1617, a potential first-in-class antibody-drug conjugate (ADC) designed for the treatment of advanced solid tumors. The investigational therapy combines an undisclosed tumor-targeting antibody with HC74, Immunome’s proprietary topoisomerase I (TOP1) inhibitor payload, marking another significant advancement in the company’s expanding oncology pipeline. The milestone highlights Immunome’s commitment to developing innovative targeted cancer therapies aimed at improving outcomes for patients with difficult-to-treat solid tumors.
Phase 1 Study Evaluates Safety and Early Anti-Tumor Activity
The ongoing Phase 1 clinical trial is an open-label, multicenter dose-escalation and expansion study designed to assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of IM-1617. The study will enroll patients with a variety of advanced solid tumors, including colorectal cancer, non-small cell lung cancer (NSCLC), and breast cancer. Researchers will evaluate escalating dose levels to identify an optimal therapeutic dose while gathering early clinical evidence regarding the ADC’s effectiveness against multiple tumor types. The initiation of patient dosing represents the transition of IM-1617 from preclinical development into human clinical testing, an important step in determining its potential as a novel cancer treatment.
Proprietary HC74 Payload Drives Next-Generation ADC Development
IM-1617 is built around an undisclosed receptor tyrosine kinase target involved in tumor growth, survival, and immune evasion. The therapy incorporates HC74, Immunome’s proprietary TOP1 inhibitor payload, which is designed to selectively deliver a potent anti-cancer agent directly to tumor cells while limiting exposure to healthy tissues. According to the company, preclinical studies demonstrated substantial tumor regression across multiple solid tumor models following a single clinically relevant dose. These findings support the scientific rationale for advancing IM-1617 into clinical development and reinforce the broader potential of HC74 as a payload platform for future ADC programs targeting a range of cancers.
Advertisement
Expanding Immunome’s Clinical Oncology Pipeline
The launch of the IM-1617 study adds momentum to Immunome’s growing portfolio of targeted oncology therapies. The company expects to continue expanding its ADC pipeline with planned Investigational New Drug (IND) submissions for IM-1340 and IM-1335 later in 2026. In addition to IM-1617, Immunome’s development portfolio includes varegacestat, an investigational gamma secretase inhibitor currently under FDA review, IM-1021, a clinical-stage ROR1-targeted ADC, and IM-3050, a fibroblast activation protein (FAP)-targeted radiotherapy candidate. By leveraging proprietary antibody and payload technologies, Immunome aims to develop first-in-class and best-in-class therapies that address significant unmet needs in oncology and expand treatment options for patients with advanced cancers
Source: Immunome press release
